Clinical trials: Inhalation
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a…
- Trial name
- NCT00703339
- Testing
- Treprostinil sodium for inhalation
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Lung Biotechnology PBC
Periodic Breathing, Cheyne-Stokes Respiration
Comparison of Modified With Conventional Adaptive Servoventilation Processes
The objective of this study is to compare the modified adaptive servoventilation control algorithm of the with the standardised algorithms of routinely-used servoventilation processes (AutoSet CS2) in terms of the effect on…
- Trial name
- NCT01037439
- Testing
- Adaptive Servo-controlled Ventilation (ASV)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- ResMed
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Diabetes, Diabetes Mellitus, Type 1
Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the pharmacokinetic profile of two different methods of insulin administration in children with type 1 diabetes.
- Trial name
- NCT00567775
- Testing
- human insulin, inhaled human insulin
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Asthma
Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.
The Kata® App is a digital therapy assistant for patients with asthma who need to inhale their therapy. Kata features inhalation trainers that shows patients in a simple and understandable way how to improve their inhalation…
- Trial name
- NCT06178341
- Testing
- Kata Inhalations-App
- Where
- 13 sites in Germany
- Volunteers
- 146 people
- Sponsor
- VisionHealth GmbH
Bronchial Asthma
Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of Inhalation aerosol PA9159, to establish maximum tolerated dose in…
- Trial name
- NCT06916273
- Testing
- PA9159 Inhalation aerosol, 60 μg one day treatment, PA9159 Inhalation aerosol, 120 μg one day treatment, PA9159 Inhalation aerosol, 240 μg one day treatment
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Parkinson, Parkinson Disease
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
Patients with Parkinson's disease (PD) are commonly treated with a combination of levodopa and a decarboxylase inhibitor (DCI). However, many PD patients experience motor fluctuations (OFF episodes), even with their regular…
- Conditions
- Parkinson, Parkinson Disease, Parkinson's Disease and Parkinsonism
- Trial name
- NCT06037590
- Testing
- Levodopa Cyclops®, INBRIJA®
- Where
- Bulgaria
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- PureIMS B.V.
Healthy Subjects
Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
- Trial name
- NCT03384290
- Testing
- PRS-060
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Asthma, Respiratory Symptoms
Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)
To evaluate the level of control of Asthma (GINA : controlled, partially controlled, not controlled) of asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low)…
- Trial name
- SAISON (NCT00882128)
- Where
- 1,051 sites in France
- Volunteers
- 3,300 people
- Sponsor
- AstraZeneca
Asthma
Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01554319
- Testing
- SB010
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Cough
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
This is a First Time in Human (FTIH) study for the sodium channel inhibitor, GSK2339345. The study is split into two parts. Part A will assess the safety and tolerability of the new drug.
- Trial name
- FTIH (NCT01494636)
- Testing
- GSK2339345 (solution), GSK2339345 (nebulised), Lidocaine
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04732221
- Testing
- Frespaciguat
- Where
- 91 sites in United States, Argentina and 16 more
- Volunteers
- 168 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients.
- Trial name
- NCT00239421
- Testing
- Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule), Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.
- Where
- 56 sites in Austria, Belgium and 6 more
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension, Ayerza Syndrome
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
- Conditions
- Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
- Trial name
- NCT00086463
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Actelion
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT01957163
- Testing
- FF, VI, UMEC
- Where
- 53 sites in United States, Argentina and 3 more
- Volunteers
- 619 people
- Sponsor
- GlaxoSmithKline
Drug Safety, Respiratory Syncytial Virus Infections
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
The purpose of this study is to determine the range of single inhaled doses of a new dry powder product, MDT-637, that are safe and well-tolerated.
- Trial name
- NCT01355016
- Testing
- MDT-637
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MicroDose Therapeutx, Inc
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
This trial is conducted in Asia, Europe and South America. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function tests, chest x-rays) of mealtime…
- Trial name
- NCT00331604
- Testing
- inhaled human insulin, insulin detemir, insulin aspart
- Where
- 73 sites in Brazil, Denmark and 9 more
- Volunteers
- 618 people
- Sponsor
- Novo Nordisk A/S
Bronchial Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.
- Trial name
- NCT06154304
- Testing
- Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Cipla Ltd.
Cardiac Arrest, Sudden Cardiac Death
Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest
More than 300,000 Americans experience out-of-hospital cardiac arrest annually, with overall survival rates averaging less than 5%.
- Trial name
- NCT01325870
- Testing
- ACD-CPR, ITPR, S-CPR
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Advanced Circulatory Systems
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.